TherapeuticsMD Q3 license revenue rises 60.6% to $1.3M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TherapeuticsMD, Inc. (TXMD) reported third-quarter 2026 license revenue from continuing operations of $1.3 million, up $475,000, or 60.6%, from $784,000 in the third quarter of 2025. The company attributed the increase primarily to an IMVEXXY sales-based milestone tied to 2025 sales.
Knight confirmed the milestone in the third quarter, resulting in a $365,000 payment recognized by TherapeuticsMD. After September 30, 2026, Knight notified the company that a separate net-sales milestone tied to IMVEXXY sales for the year ending December 31, 2026, had been achieved. TherapeuticsMD says it is entitled to a milestone payment and will recognize the related revenue in the three months ending December 31, 2026.
TherapeuticsMD says it changed its business in December 2022 to become a pharmaceutical royalty company, primarily collecting royalties from licensees. It no longer engages in research and development or commercial operations, and describes itself as owning rights to pharmaceutical royalties.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQ3 license revenue: $1.3 million, up 60.6% year over year.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
license revenue financial
sales-based milestone financial
net sales milestone financial
continuing operations financial
Earnings Snapshot
TherapeuticsMD said it will recognize revenue from an achieved net-sales milestone tied to IMVEXXY sales for the year ending December 31, 2026, in the three months ending December 31, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much license revenue did TXMD report for Q3 2026?
When will TXMD recognize revenue from its new IMVEXXY milestone?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE
OF REPORT (DATE OF EARLIEST EVENT REPORTED):
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Office) (Zip Code)
Registrant’s
telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.
Item 7.01 Regulation FD Disclosure.
On November 13, 2026, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.
The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Index
| Exhibit No. | Description | |
| 99.1 | Press Release from TherapeuticsMD, Inc., dated November 13, 2026, entitled “TherapeuticsMD Announces Second Quarter 2026 Financial Results.” | |
| 104 | Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document). | |
| 1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 13, 2026 | THERAPEUTICSMD, INC. |
| /s/ Marlan Walker | |
| Marlan Walker | |
| Chief Executive Officer |
| 2 |
Exhibit 99.1
FOR IMMEDIATE RELEASE
TherapeuticsMD Announces Third Quarter 2026 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)—November 13, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2026.
Third Quarter 2026 Financial Results
Net Income from Continuing Operations
| ● | Net income from continuing operations totaled $501 thousand, or $0.04 per basic and diluted common share, compared to income from continuing operations of $50 thousand, or $0.00 per basic and diluted common share for the third quarter of 2025. |
License Revenues from Continuing Operations
| ● | The Company recorded $1.3 million in license revenue for the third quarter of 2026, an increase of $475 thousand, or 60.6%, compared to $784 thousand in license revenue for the third quarter of 2025. The increase is primarily attributable to the achievement of an IMVEXXY sales-based milestone by Knight relating to IMVEXXY sales for the year ended December 31, 2025, resulting in a $365 thousand milestone payment that was recognized and confirmed by Knight in the third quarter of 2026. | |
| ● | Subsequent to September 30, 2026, Knight notified the Company that a net sales milestone related to IMVEXXY sales for the year ending December 31, 2026, had been achieved. Accordingly, the Company is entitled to a milestone payment and will recognize the related milestone revenue during the three months ending December 31, 2026. |
Total Operating Expenses from Continuing Operations
| ● | Total operating expenses for the third quarter of 2026 were $1.7 million, an increase of $92 thousand, or 5.6%, compared to $1.6 million for the third quarter of 2025. The increase is primarily due to higher legal and professional fees. |
Evaluation of Strategic Alternatives
| ● | The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. |
Balance Sheet
| ● | As of September 30, 2026, the Company’s cash and cash equivalents totaled $10.4 million. |
About TherapeuticsMD
TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies, including the exploration of potential strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions, and the completion of such a review process and the potential timing, outcome and ability of any such strategic alternatives to create stockholder value, as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future, including statements regarding the Company’s financial condition, liquidity, results of operations and royalty revenues. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the Company’s licensees will be successful at commercializing the products that they licensed and acquired from TherapeuticsMD; the Company’s dependence upon third parties for the manufacture and supply the Company’s women’s healthcare products; whether coverage and reimbursement is available for the Company’s products; the outcome of the Company’s ongoing disputes with Mayne Pharma; time and costs associated with winding down the Company’s operations and whether the Company is successful in its pursuit of strategic alternatives; the Company’s ability to remain listed on Nasdaq; the impact of transitions in the Company’s senior management team; the impact of government regulation, including those resulting from healthcare reform and drug pricing initiatives; whether we are able to protect the proprietary nature of the intellectual property covering the Company’s hormone therapy pharmaceutical products; competition from branded and generic products; and the Company’s ability to continue as a going concern.
Contact:
Lisa M. Wilson
In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
Source: TherapeuticsMD, Inc.